Immuneering Corp., a Cambridge, Mass.-based startup that uses computational technology for drug discovery, completed a $62 million Series B round. Cormorant Asset Management led the financing, which included participation from Surveyor Capital, Rock Springs Capital, funds and accounts advised by T. Rowe Price Associates Inc., funds and accounts managed by BlackRock, Perceptive Advisors and LYFE Capital.